Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally
Authors:
Open Access
- 7 September 2021
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (1) , 415-424
Abstract
Background: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. Our report describes the evolution of management and characteristics associated with recurrence, disease-specific survival (DSS) and overall survival (OS) in the treatment of MCC. Methods: A single institution retrospective review of MCC and SEER data to determine factors associated with RFS, DSS, and OS using a multivariable Cox regression on inverse-probability weighted cohorts. Results: One hundred fifty-nine patients were identified with a median age of 75. Of these, 96% were Caucasian and 60% male. Fifty-eight out of 159 (36%) of all patients were deceased with 21/58 (36%) dead from MCC with a median follow-up of 3.1 years. Institutionally, trends over time demonstrated an increased use of immunotherapy with a concomitant decrease in chemotherapy and decreased use of radiotherapy alone. Institutionally and nationally, there has been increased surgical nodal staging. Institutionally, factors associated with shorter DSS included advanced age, active cigarette smoker (p = 0.002), cT2 disease (p = 0.007), and MCC with unknown primary (p < 0.001). Institutionally, factors associated with shorter OS included ages ≥ 75 years (p < 0.001), an immunocompromised state (p < 0.001), truncal primary site (p = 0.002), and cT2 disease (HR 9.59, p < 0.001). Conclusion: Changing practice patterns in MCC management have been driven by the adoption of immunotherapy. Our study highlights that competing risks of mortality in MCC patients likely prevents OS from being an accurate surrogate outcome measure to understand factors associated with DSS.Keywords
This publication has 28 references indexed in Scilit:
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell CarcinomaNew England Journal of Medicine, 2016
- Effect of Host, Tumor, Diagnostic, and Treatment Variables on Outcomes in a Large Cohort With Merkel Cell CarcinomaJAMA Dermatology, 2014
- Merkel Cell Carcinoma: 30-Year Experience from a Single InstitutionAnnals of Surgical Oncology, 2012
- Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging systemJournal of the American Academy of Dermatology, 2010
- Clonal Integration of a Polyomavirus in Human Merkel Cell CarcinomaScience, 2008
- Merkel Cell Carcinoma: Assessing the Effect of Wide Local Excision, Lymph Node Dissection, and Radiotherapy on Recurrence and Survival in Early-Stage Disease—Results From a Review of 82 Consecutive Cases Diagnosed Between 1992 and 2004Annals of Surgical Oncology, 2007
- Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized TrialsJournal of Clinical Oncology, 2005
- Merkel Cell Carcinoma: Prognosis and Treatment of Patients From a Single InstitutionJournal of Clinical Oncology, 2005
- A Meta-analysis of the Prognostic Significance of Sentinel Lymph Node Status in Merkel Cell CarcinomaDermatologic Surgery, 2002
- Trabecular Carcinoma of the SkinArchives of Dermatology, 1972